Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAT1 | P21673 | 1/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.35 |
| ▸ | HOGA1 | Q86XE5 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19781517 | 0.87 | SAT1 (0.33) | SAT1GNAI3GNAO1GNAI1 | |
| SCHEMBL19098395 | 0.86 | GNAI3 (0.42) | SAT1GNAI3GNAO1GNAI1 | |
| SCHEMBL19782073 | 0.82 | SAT1 (0.38) | SAT1GNAI3GNAO1GNAI1 | |
| SCHEMBL19779756 | 0.79 | SAT1 (0.36) | SAT1GNAI3GNAO1GNAI1 | |
| SCHEMBL19781522 | 0.78 | SAT1 (0.38) | SAT1GNAI3GNAO1GNAI1KDM4E | |
| SCHEMBL24922554 | 0.78 | — | — | |
| SCHEMBL19782060 | 0.77 | GNAI3 (0.33) | SAT1GNAI3GNAO1GNAI1 | |
| SCHEMBL3427404 | 0.75 | — | — | |
| SCHEMBL19880465 | 0.74 | SAT1 (0.37) | SAT1GNAI3GNAO1GNAI1 | |
| SCHEMBL21883700 | 0.74 | SAT1 (0.37) | SAT1GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2018-01-18 | — | — | US | disclosed |
| WO-2018013676-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | SAT1 2401/4885GNAI3 572/4885GNAO1 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.